Aug 01, 2019 XOMA Congratulates Rezolute on its Successful Financing and Progress Towards Initiating Phase 2b Study for RZ358
Mar 10, 2020 • 7:30 AM EDT XOMA Reports Fourth Quarter and Full-Year 2019 Financial Results and Operating Highlights
Mar 9, 2020 • 5:00 AM EDT Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement
Feb 25, 2020 • 4:30 PM EST XOMA to Present at the Cowen and Company 40th Annual Health Care Conference
